Published in JAMA on November 06, 2013
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clin Cancer Res (2015) 1.73
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol (2014) 1.26
Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol (2014) 1.24
Mechanisms regulating glioma invasion. Cancer Lett (2015) 1.19
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun (2015) 1.07
A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway. Oncotarget (2014) 1.06
Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol (2015) 1.05
Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? Ann Transl Med (2015) 1.04
Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase. PLoS One (2014) 1.03
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res (2014) 0.98
Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proc Natl Acad Sci U S A (2015) 0.97
Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer (2015) 0.97
Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov (2014) 0.95
Intravoxel incoherent motion diffusion-weighted MR imaging of gliomas: efficacy in preoperative grading. Sci Rep (2014) 0.95
Differential lncRNA expression profiles in recurrent gliomas compared with primary gliomas identified by microarray analysis. Int J Clin Exp Med (2015) 0.95
Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. Oncotarget (2014) 0.95
miR-340 suppresses glioblastoma multiforme. Oncotarget (2015) 0.94
Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner. Cancer Cell (2016) 0.94
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. Clin Cancer Res (2015) 0.94
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother (2014) 0.91
Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos Trans R Soc Lond B Biol Sci (2015) 0.91
Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res (2014) 0.90
Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances. Mater Today (Kidlington) (2016) 0.90
Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells. Oncoscience (2014) 0.89
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. Oncotarget (2016) 0.88
Transcriptional diversity of long-term glioblastoma survivors. Neuro Oncol (2014) 0.87
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. J Cell Physiol (2015) 0.87
Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells (2014) 0.87
Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, β-Catenin, CBP, and STAT3. PLoS One (2014) 0.87
Physiological and pathophysiological roles for phospholipase D. J Lipid Res (2015) 0.86
Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed Res Int (2014) 0.86
Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes. BMC Genomics (2016) 0.85
Novel paracrine modulation of Notch-DLL4 signaling by fibulin-3 promotes angiogenesis in high-grade gliomas. Cancer Res (2014) 0.85
Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep (2016) 0.85
GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy. Glia (2014) 0.85
Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysis. Mol Med Rep (2014) 0.84
Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation. Oncotarget (2014) 0.84
Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev (2014) 0.83
ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors. Mol Pharm (2016) 0.82
Autophagy Induction by Endothelial-Monocyte Activating Polypeptide II Contributes to the Inhibition of Malignant Biological Behaviors by the Combination of EMAP II with Rapamycin in Human Glioblastoma. Front Mol Neurosci (2015) 0.82
miR-21 induces cell proliferation and suppresses the chemosensitivity in glioblastoma cells via downregulation of FOXO1. Int J Clin Exp Med (2014) 0.82
EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. Oncotarget (2015) 0.82
Acute ischemic stroke secondary to glioblastoma. A case report. Neuroradiol J (2014) 0.82
Successful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug. EBioMedicine (2015) 0.82
Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme. Onco Targets Ther (2016) 0.82
Suppression of lactate dehydrogenase A compromises tumor progression by downregulation of the Warburg effect in glioblastoma. Neuroreport (2016) 0.82
Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces (2015) 0.81
Neurocognitive features distinguishing primary central nervous system lymphoma from other possible causes of rapidly progressive dementia. Cogn Behav Neurol (2015) 0.81
MiR224-3p inhibits hypoxia-induced autophagy by targeting autophagy-related genes in human glioblastoma cells. Oncotarget (2015) 0.81
Immunotherapy for malignant glioma. Surg Neurol Int (2015) 0.81
Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Eur J Nucl Med Mol Imaging (2016) 0.81
Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathol (2015) 0.80
LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells. Cell Stress Chaperones (2015) 0.80
Treatment of malignant gliomas in elderly patients: a concise overview of the literature. Biomed Res Int (2014) 0.80
Imaging biomarkers in primary brain tumours. Eur J Nucl Med Mol Imaging (2014) 0.80
Genetically modified T cells to target glioblastoma. Front Oncol (2013) 0.80
Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry. Int J Cancer (2014) 0.80
The role of NF-κB in the pathogenesis of glioma. Mol Cell Oncol (2014) 0.80
Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential. Peptides (2014) 0.80
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. Mol Med Rep (2015) 0.80
Up-Regulation of Long Non-Coding RNA AB073614 Predicts a Poor Prognosis in Patients with Glioma. Int J Environ Res Public Health (2016) 0.80
LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway. Int J Clin Exp Pathol (2015) 0.79
Ablation of Neuropilin 1 from glioma-associated microglia and macrophages slows tumor progression. Oncotarget (2016) 0.79
High expression of WDR1 in primary glioblastoma is associated with poor prognosis. Am J Transl Res (2016) 0.79
H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma. Am J Transl Res (2015) 0.79
Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma. Int J Nanomedicine (2016) 0.79
Autophagy and radiosensitization in cancer. EXCLI J (2014) 0.79
Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther (2016) 0.79
The taxonomy of brain cancer stem cells: what's in a name? Oncoscience (2014) 0.79
IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS One (2015) 0.79
Evolving Molecular Genetics of Glioblastoma. Chin Med J (Engl) (2016) 0.79
Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma. Exp Ther Med (2015) 0.79
A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res (2016) 0.79
Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ. Oncotarget (2016) 0.79
COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value. Oncotarget (2016) 0.79
Taspase1: a 'misunderstood' protease with translational cancer relevance. Oncogene (2015) 0.78
Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers. Paediatr Drugs (2014) 0.78
Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia. PLoS One (2014) 0.78
Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunol Rev (2017) 0.78
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther (2014) 0.78
Malignant gliomas: old and new systemic treatment approaches. Radiol Oncol (2016) 0.78
Cytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment options. World J Exp Med (2015) 0.78
Di-ethylhexylphthalate (DEHP) modulates cell invasion, migration and anchorage independent growth through targeting S100P in LN-229 glioblastoma cells. Int J Environ Res Public Health (2014) 0.78
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma. Sci Rep (2015) 0.78
All-trans retinoic acid impairs the vasculogenic mimicry formation ability of U87 stem-like cells through promoting differentiation. Mol Med Rep (2015) 0.78
Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res (2016) 0.78
Silence of MACC1 expression by RNA interference inhibits proliferation, invasion and metastasis, and promotes apoptosis in U251 human malignant glioma cells. Mol Med Rep (2015) 0.78
BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide. Int J Mol Med (2015) 0.78
Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy. CNS Oncol (2014) 0.78
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis. Oncotarget (2016) 0.78
Inhibition of REST Suppresses Proliferation and Migration in Glioblastoma Cells. Int J Mol Sci (2016) 0.78
The potential role of exercise in neuro-oncology. Front Oncol (2015) 0.78
Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas. Eur Radiol (2015) 0.77
Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol (2017) 0.77
MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. Mol Cancer Res (2016) 0.77
Tomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase. Cancer Gene Ther (2015) 0.77
Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma. Pak J Med Sci (2015) 0.77
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Brain metastases. Neurol Clin (2003) 2.44
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2004) 2.41
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13
Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci (2003) 1.99
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology (2005) 1.91
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma (2003) 1.77
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol (2006) 1.74
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol (2009) 1.58
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol (2013) 1.54
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Chemotherapy for brain tumors--a new beginning. N Engl J Med (2005) 1.49
Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol (2004) 1.48
Multifocal stroke from tumor emboli. Arch Neurol (2009) 1.48
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology (2007) 1.43
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol (2003) 1.41
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol (2008) 1.37
Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol (2007) 1.36
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol (2008) 1.36
Herpes simplex encephalitis in patients with cancer. J Neurooncol (2011) 1.32
Glioblastoma: molecular analysis and clinical implications. Annu Rev Med (2012) 1.31
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol (2012) 1.27
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J Clin Oncol (2009) 1.22
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol (2008) 1.18
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer (2005) 1.15
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology (2004) 1.15
Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology (2006) 1.14
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer (2010) 1.11
An update on primary central nervous system lymphoma. Hematol Oncol Clin North Am (2006) 1.11
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer (2012) 1.08
Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme. Neurology (2007) 1.02
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol (2006) 1.02
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00
Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol (2007) 0.97
Primary CNS lymphoma: a whole-brain disease? Neurology (2002) 0.97
Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol (2006) 0.96
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol (2002) 0.96
Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology (2012) 0.96
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol (2011) 0.94
Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol (2011) 0.92
MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell (2012) 0.92
Neurological outcome of long-term glioblastoma survivors. J Neurooncol (2009) 0.92
Ischemic stroke in patients with primary brain tumors. Neurology (2008) 0.91
Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease. J Neurooncol (2012) 0.90
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol (2003) 0.90
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol (2008) 0.88
Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am (2005) 0.87
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer (2008) 0.87
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol (2006) 0.87
Intracranial hemorrhage in patients with cancer. Curr Atheroscler Rep (2012) 0.86
Sarcoidosis presenting as brainstem ischemic stroke. Neurology (2009) 0.86
Neurologic complications of leukemia. Curr Opin Neurol (2002) 0.86
Brain metastases. Neurol Clin (2007) 0.86
Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
Stroke in cancer patients. Curr Neurol Neurosci Rep (2006) 0.84
Chemotherapy for low-grade gliomas: emerging consensus on its benefits. Neurology (2007) 0.84
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs (2005) 0.83
A better way to find tumor in the CSF? Neurology (2002) 0.83
Use of diffusion weighted magnetic resonance imaging in predicting early postoperative outcome of new neurological deficits after brain tumor resection. Neurosurgery (2006) 0.82
LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. Br J Haematol (2014) 0.82
Primary central nervous system lymphoma: a curable brain tumor. J Clin Oncol (2003) 0.82
Neurologic complications of chemotherapy and radiation therapy. Continuum (Minneap Minn) (2015) 0.82
Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy. Cancer (2010) 0.82
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology (2005) 0.81
Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities. Arch Neurol (2004) 0.81
Multifocal strokes as the presentation of occult lung cancer. J Neurooncol (2007) 0.81
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res (2007) 0.81
Virchow 2011 or how to ID(H) human glioblastoma. J Clin Oncol (2011) 0.81
Central nervous system cancers. J Natl Compr Canc Netw (2008) 0.79
Diagnostic yield of echocardiography in cancer patients with ischemic stroke. J Neurooncol (2015) 0.79
Radiotherapy and temozolomide for anaplastic astrocytic gliomas. J Neurooncol (2015) 0.79
Retinopathy in survivors of primary central nervous system lymphoma. Neurology (2006) 0.78
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol (2013) 0.78
It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol (2011) 0.77
High-grade gliomas in patients with prior systemic malignancies. Cancer (2002) 0.76
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys (2010) 0.76
Natalizumab: a double-edged sword? Ann Neurol (2009) 0.75
Spectrum of nonconvulsive status epilepticus in patients with cancer. J Clin Neurophysiol (2013) 0.75
Delayed infection of the Ommaya reservoir. Neurology (2002) 0.75
Treatment of primary central nervous system lymphoma. Curr Neurol Neurosci Rep (2007) 0.75
Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings. Clin Adv Hematol Oncol (2003) 0.75
Nervous system neoplasms. Adv Neurol (2002) 0.75
The confused oncologic patient: a rational clinical approach. Curr Opin Neurol (2016) 0.75
Chemotherapy-Induced Peripheral Neuropathy. Oncology (Williston Park) (2016) 0.75
Electrophysiological features of taxane-induced polyneuropathy in patients with breast cancer. J Clin Neurophysiol (2013) 0.75
Response to chemotherapy of a radiation-induced glioblastoma multiforme. J Neurooncol (2006) 0.75
Management of elderly patients with primary central nervous system lymphoma. Curr Neurol Neurosci Rep (2013) 0.75